Laurion Capital Management LP Has $2.43 Million Holdings in REGENXBIO Inc. (RGNX)

Laurion Capital Management LP grew its position in REGENXBIO Inc. (NASDAQ:RGNX) by 354.0% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 123,028 shares of the biotechnology company’s stock after purchasing an additional 95,928 shares during the period. Laurion Capital Management LP owned about 0.40% of REGENXBIO worth $2,430,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of RGNX. Legal & General Group Plc raised its holdings in REGENXBIO by 41.4% in the second quarter. Legal & General Group Plc now owns 6,870 shares of the biotechnology company’s stock worth $137,000 after purchasing an additional 2,011 shares during the period. Oxford Asset Management acquired a new stake in REGENXBIO in the first quarter worth $206,000. American International Group Inc. raised its holdings in REGENXBIO by 7.1% in the first quarter. American International Group Inc. now owns 12,468 shares of the biotechnology company’s stock worth $241,000 after purchasing an additional 822 shares during the period. Acadian Asset Management LLC acquired a new stake in REGENXBIO in the first quarter worth $272,000. Finally, Wells Fargo & Company MN raised its holdings in REGENXBIO by 1.1% in the second quarter. Wells Fargo & Company MN now owns 16,209 shares of the biotechnology company’s stock worth $320,000 after purchasing an additional 175 shares during the period. Institutional investors own 73.23% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This story was first published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this story on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this story can be viewed at https://www.chaffeybreeze.com/2017/09/20/laurion-capital-management-lp-has-2-43-million-holdings-in-regenxbio-inc-rgnx.html.

RGNX has been the topic of several analyst reports. Chardan Capital increased their target price on shares of REGENXBIO from $50.00 to $55.00 and gave the stock a “buy” rating in a report on Wednesday, August 9th. Zacks Investment Research lowered shares of REGENXBIO from a “buy” rating to a “hold” rating in a report on Thursday, August 17th. Evercore ISI initiated coverage on shares of REGENXBIO in a report on Wednesday, August 16th. They issued an “outperform” rating and a $25.00 target price on the stock. Finally, BidaskClub upgraded shares of REGENXBIO from a “hold” rating to a “buy” rating in a report on Saturday, August 12th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $37.00.

Shares of REGENXBIO Inc. (NASDAQ:RGNX) opened at 29.05 on Wednesday. The firm has a 50-day moving average of $27.39 and a 200 day moving average of $27.39. The firm’s market capitalization is $897.47 million. REGENXBIO Inc. has a 12-month low of $13.61 and a 12-month high of $30.25.

REGENXBIO (NASDAQ:RGNX) last posted its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.47) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.81) by $0.34. REGENXBIO had a negative net margin of 839.87% and a negative return on equity of 38.74%. The company had revenue of $6.56 million for the quarter. On average, equities research analysts expect that REGENXBIO Inc. will post ($2.87) earnings per share for the current year.

In related news, CFO Vittal Vasista sold 5,000 shares of the stock in a transaction on Friday, September 15th. The shares were sold at an average price of $27.39, for a total transaction of $136,950.00. Following the transaction, the chief financial officer now directly owns 99,594 shares of the company’s stock, valued at $2,727,879.66. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Donald J. Hayden, Jr. sold 40,000 shares of the stock in a transaction on Monday, September 18th. The stock was sold at an average price of $28.70, for a total transaction of $1,148,000.00. Following the transaction, the director now directly owns 20,000 shares in the company, valued at $574,000. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 154,640 shares of company stock worth $3,923,590. Insiders own 17.00% of the company’s stock.

About REGENXBIO

REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.

Want to see what other hedge funds are holding RGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for REGENXBIO Inc. (NASDAQ:RGNX).

Institutional Ownership by Quarter for REGENXBIO (NASDAQ:RGNX)

Receive News & Ratings for REGENXBIO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply